Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 18. Отображено 18.
04-01-2018 дата публикации

PD-L1-SPECIFIC ANTIBODIES AND METHODS OF USING THE SAME

Номер: US20180002424A1
Автор: BELK Jonathan, Gorelik Leonid, Sharkey Nathan J.
Принадлежит: Checkpoint Therapeutics, Inc.

The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer. 1. An antibody or a functional fragment thereof that binds to human programmed death-ligand 1 (PD-L1) , wherein the antibody or functional fragment thereof comprises:a heavy chain comprising: CDRH1 comprising amino acids 1-3 and 7-9 of SEQ ID NO: 1, wherein amino acids 4-6 are not SSY; CDRH2 comprising amino acids 9-17 of SEQ ID NO: 8; and CDRH3 comprising SEQ ID NO: 15; anda light chain comprising CDRL1 comprising SEQ ID NO: 20; CDRL2 comprising SEQ ID NO: 21; and CDRL3 comprising SEQ ID NO: 22, SEQ ID NO: 75, or SEQ ID NO: 76.2. The antibody or functional fragment thereof according to claim 1 , wherein the CDRH1 region comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 2 claim 1 , 3 claim 1 , 4 claim 1 , 5 claim 1 , 6 and 7.3. The antibody or functional fragment thereof according to claim 1 , wherein the CDRH2 region comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 8 claim 1 , 9 claim 1 , 10 claim 1 , 11 claim 1 , 12 claim 1 , 13 and 14.4. The antibody or functional fragment thereof according to claim 1 , wherein the variable heavy framework region 1 comprises SEQ ID NO. 26.5. The antibody or functional fragment thereof according to claim 1 , wherein the variable heavy framework region 1 comprises SEQ ID NO. 27.6. The antibody or functional fragment thereof according to claim 1 , wherein the variable heavy framework region 2 comprises SEQ ID NO. 28.7. The antibody or functional fragment thereof according to ...

Подробнее
Номер записи: 1
19-03-2020 дата публикации

ALK7 BINDING PROTEINS AND USES THEREOF

Номер: US20200087406A1
Автор: BELK Jonathan, Castonguay Roselyne, DAGON Yossi, Grinberg Asya, Knopf John, Kumar Ravindra, Sako Dianne, Sharkey Nathan J.
Принадлежит:

This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7. 1. An activin receptor-Like Kinase 7 (ALK7)-binding protein comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 117 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 124 ,wherein the protein binds to ALK7.2. (canceled)3. An ALK7-binding protein comprising a set of CDRs in which:(i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO: 114;(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO: 15;(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO: 116;(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:121;(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO: 122; and(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:123;wherein the protein binds ALK7.419-. (canceled)20. The ALK7-binding protein of claim 1 , wherein the ALK7-binding protein is antibody claim 1 , wherein the antibody is a monoclonal antibody claim 1 , a recombinant antibody claim 1 , a human antibody claim 1 , a humanized antibody claim 1 , a chimeric antibody claim 1 , a bi-specific antibody claim 1 , a multi-specific antibody claim 1 , or an ALK7-binding antibody fragment.21. The ALK7-binding protein of claim 20 , wherein the ALK7-binding antibody fragment is selected from the group consisting of a Fab fragment claim 20 , a Fab′ fragment claim 20 , a F(ab′)fragment claim 20 , a Fv fragment claim 20 , a diabody claim 20 , or a single chain antibody ...

Подробнее
Номер записи: 2
03-09-2020 дата публикации

PD-L1-SPECIFIC ANTIBODIES AND METHODS OF USING THE SAME

Номер: US20200277380A1
Автор: BELK Jonathan, Gorelik Leonid, Sharkey Nathan J.
Принадлежит: Checkpoint Therapeutics Inc.

The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer. 124-. (canceled)25. A method of treating cancer , comprising administering to a subject with cancer an antibody or a fragment thereof that binds to human programmed death-ligand 1 (PD-L1) and comprises: a heavy chain comprising a complementarity determining region (CDR) H1 comprising any one of SEQ ID NOs: 2 , 3 , 4 , 5 , 6 , or 7 , a CDRH2 comprising any one of SEQ ID NOs: 8 , 9 , 10 , 11 , 12 , 13 , or 14 , and a CDRH3 comprising SEQ ID NO: 15; and a light chain comprising a CDRL1 comprising SEQ ID NO: 20 , a CDRL2 comprising SEQ ID NO: 21; and CDRL3 comprising any one of SEQ ID NOs: 22 , 75 , or 76.26. The method of claim 25 , wherein the cancer is lung cancer claim 25 , melanoma claim 25 , renal cell carcinoma (RCC) claim 25 , head and neck cancer claim 25 , or bladder cancer.27. The method of claim 26 , wherein the lung cancer is non-small cell lung cancer (NSCLC).28. The method of claim 25 , wherein the cancer is a carcinoma.29. The method of claim 25 , wherein the heavy chain comprises any one of SEQ ID NOs: 36 claim 25 , 37 claim 25 , 38 claim 25 , 39 claim 25 , 40 claim 25 , or 41 claim 25 , and the light chain comprises SEQ ID NO: 42.30. The method of claim 29 , wherein the cancer is lung cancer claim 29 , melanoma claim 29 , renal cell carcinoma (RCC) claim 29 , head and neck cancer claim 29 , or bladder cancer.31. The method of claim 30 , wherein the lung cancer is non-small cell lung cancer (NSCLC).32. The method of claim 25 , wherein the antibody or fragment ...

Подробнее
Номер записи: 3
26-10-2017 дата публикации

ALK7 Binding Proteins and Uses Thereof

Номер: US20170306028A1
Автор: BELK Jonathan, Castonguay Roselyne, DAGON Yossi, Grinberg Asya, Knopf John, Kumar Ravindra, Sako Dianne, Sharkey Nathan J.
Принадлежит:

This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7. 1. An isolated activin receptor-Like Kinase 7 (ALK7)-binding protein comprising a set of CDRs: VH-CDR1 , VH-CDR2 , VH-CDR3 , VL-CDR1 , VL-CDR2 and VL-CDR3 , wherein the CDRs are from a heavy chain variable region (VH) and a light chain variable region (VL) pair selected from the group consisting of: '(ii) a VL sequence of SEQ ID NO:110;', '(a) (i) a VH sequence of SEQ ID NO:105, and'} '(ii) a VL sequence of SEQ ID NO:124;', '(b) (i) a VH sequence of SEQ ID NO:117, and'} '(ii) a VL sequence of SEQ ID NO:135;', '(c) (i) a VH sequence of SEQ ID NO:128, and'} '(ii) a VL sequence of SEQ ID NO:148;', '(d) (i) a VH sequence of SEQ ID NO:140, and'} '(ii) a VL sequence of SEQ ID NO:98;', '(e) (i) a VH sequence of SEQ ID NO:91, and'} '(ii) a VL sequence of SEQ ID NO:13;', '(f) (i) a VH sequence of SEQ ID NO:4, and'} '(ii) a VL sequence of SEQ ID NO:98;', '(g) (i) a VH sequence of SEQ ID NO:152, and'} '(ii) a VL sequence of SEQ ID NO:110;', '(h) (i) a VH sequence of SEQ ID NO:159, and'} '(ii) a VL sequence of SEQ ID NO:171;', '(i) (i) a VH sequence of SEQ ID NO:165, and'} '(ii) a VL sequence of SEQ ID NO:31;', '(j) (i) a VH sequence of SEQ ID NO:22, and'} '(ii) a VL sequence of SEQ ID NO:49;', '(k) (i) a VH sequence of SEQ ID NO:40, and'} '(ii) a VL sequence of SEQ ID NO:67; and', '(l) (i) a VH sequence of SEQ ID NO:58, and'}wherein the protein binds to ALK7.2. An isolated ALK7-binding protein comprising a set of CDRs: VH-CDR1 , VH-CDR2 , VH- ...

Подробнее
Номер записи: 4
17-12-2020 дата публикации

ALK7 BINDING PROTEINS AND USES THEREOF

Номер: US20200392233A1
Автор: BELK Jonathan, Castonguay Roselyne, Kumar Ravindra, Sako Dianne, Sharkey Nathan J.
Принадлежит:

This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7. 1. An Activin Receptor-Like Kinase 7 (ALK7)-binding protein that specifically binds at least one primary epitope of an ALK7 protein , wherein the at least one primary epitope is essentially the same as an epitope selected from SEQ ID NOs:310 , 313 , and 317.2. The ALK7-binding protein of claim 1 , further specifically binds at least one conformational epitope of an ALK7 protein claim 1 , wherein the at least one conformational epitope is essentially the same as an epitope selected from SEQ ID NOs:311 claim 1 , 312 claim 1 , 314 claim 1 , 315 claim 1 , 316 claim 1 , 318 claim 1 , and 319.3. (canceled)4. The ALK7-binding protein of claim 1 , comprising a set of CDRs: VH-CDR1 claim 1 , VH-CDR2 claim 1 , VH-CDR3 claim 1 , VL-CDR1 claim 1 , VL-CDR2 and VL-CDR3 claim 1 , wherein the CDRs are from a heavy chain variable region (VH) and a light chain variable region (VL) pair selected from: '(ii) a VL sequence of SEQ ID NO:124;', '(a) (i) a VH sequence of SEQ ID NO:117, and'} '(ii) a VL sequence of SEQ ID NO:110;', '(b) (i) a VH sequence of SEQ ID NO:105, and'} '(ii) a VL sequence of SEQ ID NO:135;', '(c) (i) a VH sequence of SEQ ID NO:128, and'} '(ii) a VL sequence of SEQ ID NO:148;', '(d) (i) a VH sequence of SEQ ID NO:140, and'} '(ii) a VL sequence of SEQ ID NO:98;', '(e) (i) a VH sequence of SEQ ID NO:91, and'} '(ii) a VL sequence of SEQ ID NO:13;', '(f) (i) a VH sequence of SEQ ID NO:4, and'} '(ii) a VL sequence of SEQ ID NO:98;', '(g) ( ...

Подробнее
Номер записи: 5
03-11-2022 дата публикации

ALK7 BINDING PROTEINS AND USES THEREOF

Номер: US20220348685A1
Автор: BELK Jonathan, Castonguay Roselyne, DAGON Yossi, Grinberg Asya, Knopf John, Kumar Ravindra, Sako Dianne, Sharkey Nathan J.
Принадлежит:

This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments, the ALK7-binding proteins inhibit or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7. 2. (canceled)4. (canceled)6. The ALK7-binding protein of claim 1 , comprising a VH and VL pair selected from: '(ii) a VL having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:13;', '(a) (i) a VH having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:4, and'} '(ii) a VL having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:31;', '(b) (i) a VH having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:22, and'} '(ii) a VL having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:49; or', '(c) (i) a VH having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:40, and'} (ii) a VL having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:67,', 'wherein the protein binds ALK7., '(d) (i) a VH having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:58, and'}7. The ALK7-binding protein of claim 6 , wherein the VH and VL pair is selected from:(a) a VH sequence of SEQ ID NO:4 and a VL sequence of SEQ ID NO:13;(b) a VH sequence of SEQ ID NO:22 and a VL sequence of SEQ ID NO:31;(c) a VH sequence of SEQ ID NO:40 and a VL sequence of SEQ ID NO:49; or 'wherein the protein binds ALK7.', '(d) a VH sequence of SEQ ID NO:58 and a VL sequence of SEQ ID NO:67,'}817-. (canceled)18. The ALK7-binding protein of claim 1 , wherein the ...

Подробнее
Номер записи: 6
26-10-2017 дата публикации

Alk7 binding proteins and uses thereof

Номер: CA3018272A1
Автор: Asya Grinberg, Dianne Sako, John Knopf, Jonathan Belk, Nathan J. Sharkey, Ravindra Kumar, Roselyne Castonguay, Yossi Dagon
Принадлежит: Acceleron Pharma Inc, ADIMAB LLC

This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.

Подробнее
Номер записи: 7
04-01-2018 дата публикации

Pd-l1-specific antibodies and methods of using the same

Номер: CA3027204A1
Автор: Jonathan Belk, Leonid Gorelik, Nathan J. Sharkey
Принадлежит: Checkpoint Therapeutics Inc

The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-Ll). In particular, the disclosed antibodies and fragments bind to human PD-Ll and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.

Подробнее
Номер записи: 8
02-04-2019 дата публикации

specific pd-l1 antibodies and methods of use

Номер: BR112018076684A2
Автор: BELK Jonathan, Gorelik Leonid, J. Sharkey Nathan
Принадлежит: Checkpoint Therapeutics, Inc

a presente divulgação se refere, em geral, a anticorpos e fragmentos funcionais ligantes dos mesmos que se ligam ao ligante de morte programada 1 (pd-l1). em particular, os anticorpos e fragmentos descritos se ligam à pd-l1 humana e compreendem novas regiões de determinação complementares (cdrs) também aqui descritas. por fim, a presente divulgação se refere a administração doas anticorpos e fragmentos descritos a indivíduos com câncer, assim, tratando ou diminuindo a progressão ou proliferação do câncer. The present disclosure generally relates to antibodies and functional ligand fragments thereof that bind to programmed death ligand 1 (pd-11). in particular, the described antibodies and fragments bind to human pd-11 and comprise novel complementary determining regions (cdrs) also described herein. Finally, the present disclosure relates to the administration of antibodies and fragments described to cancer individuals, thereby treating or decreasing cancer progression or proliferation.

Подробнее
Номер записи: 9
02-05-2019 дата публикации

Alk7 binding proteins and uses thereof

Номер: CA3079963A1
Автор: Dianne Sako, Jonathan Belk, Nathan J. Sharkey, Ravindra Kumar, Roselyne Castonguay
Принадлежит: Acceleron Pharma Inc, ADIMAB LLC

This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.

Подробнее
Номер записи: 10
21-02-2024 дата публикации

Ａｌｋ７結合タンパク質およびその使用

Номер: JP2024023278A
Автор: BELK Jonathan, Castonguay Roselyne, J Sharkey Nathan, Kumar Ravindra, Sako Dianne, カストングアイ，ロゼリン, クマール，ラビンドラ, サコ，ダイアン, ジェイ． シャーキー，ネイサン, ベルク，ジョナサン
Принадлежит: Acceleron Pharma Inc, ADIMAB LLC

【課題】本開示は、抗ＡＬＫ７抗体などのＡＬＫ７結合タンパク質、ならびに組成物およびＡＬＫ７結合タンパク質を製造するための方法を提供する。【解決手段】ＡＬＫ７タンパク質の少なくとも１つの一次エピトープに特異的に結合するアクチビン受容体様キナーゼ７（ＡＬＫ７）結合タンパク質であって、前記少なくとも１つの一次エピトープが特定の配列を有する３種類のエピトープと本質的に同じである、前記ＡＬＫ７結合タンパク質を提供する。【選択図】なし

Подробнее
Номер записи: 11
05-12-2023 дата публикации

PD-L1-specific antibodies and methods of using the same

Номер: US11834505B2
Автор: Jonathan Belk, Leonid Gorelik, Nathan J. Sharkey
Принадлежит: Checkpoint Therapeutics Inc

The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.

Подробнее
Номер записи: 12
28-12-2023 дата публикации

ALK7 Binding Proteins and Uses Thereof

Номер: US20230416379A1
Автор: Asya Grinberg, Dianne Sako, John Knopf, Jonathan Belk, Nathan J. Sharkey, Ravindra Kumar, Roselyne Castonguay, Yossi Dagon
Принадлежит: Acceleron Pharma Inc

This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.

Подробнее
Номер записи: 13
14-05-2024 дата публикации

ALK7 binding proteins and uses thereof

Номер: US11981738B2
Автор: Dianne Sako, Jonathan Belk, Nathan J. Sharkey, Ravindra Kumar, Roselyne Castonguay
Принадлежит: Acceleron Pharma Inc

The disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments, the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, obesity, type 2 diabetes, and their associated conditions, metabolic disorders, and other diseases or conditions that can be treated by targeting ALK7.

Подробнее
Номер записи: 14
09-05-2024 дата публикации

Pd-l1-specific antibodies and methods of using the same

Номер: US20240150468A1
Автор: Jonathan Belk, Leonid Gorelik, Nathan J. Sharkey
Принадлежит: Checkpoint Therapeutics Inc

The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.

Подробнее
Номер записи: 15
01-08-2024 дата публикации

PD-L1-specific antibodies and methods of using the same

Номер: AU2017290709B2
Автор: Jonathan Belk, Leonid Gorelik, Nathan J. Sharkey
Принадлежит: Checkpoint Therapeutics Inc

The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-Ll). In particular, the disclosed antibodies and fragments bind to human PD-Ll and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.

Подробнее
Номер записи: 16
22-08-2024 дата публикации

ALK7 binding proteins and uses thereof

Номер: AU2017252574B2
Автор: Asya Grinberg, Dianne Sako, John Knopf, Jonathan Belk, Nathan J. Sharkey, Ravindra Kumar, Roselyne Castonguay, Yossi Dagon
Принадлежит: Acceleron Pharma Inc, ADIMAB LLC

This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.

Подробнее
Номер записи: 17
29-08-2024 дата публикации

ALK7 Binding Proteins and Uses Thereof

Номер: US20240287196A1
Автор: Dianne Sako, Jonathan Belk, Nathan J. Sharkey, Ravindra Kumar, Roselyne Castonguay
Принадлежит: Acceleron Pharma Inc

This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented, or ameliorated by targeting ALK7.

Подробнее
Номер записи: 18